To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Estrogen Plus Androgen Therapy Improves Libido, Reduces Hot Flashes URL: http://www.pslgroup.com/dg/34622.htm Doctor's Guide August 8, 1997
COPENHAGEN, DENMARK -- August 8, 1997 -- Adding small amounts of androgen to estrogen replacement therapy can restore failing libido, resolve persistent hot flashes and restore decreased bone density, all consequences of menopause that can affect the quality of life and health of postmenopausal women. These findings and others were presented at a symposium entitled "The Emerging Role of Estrogen-Androgen Therapy in the Care of the Postmenopausal Patient," at the XV World Congress of Gynecology and Obstetrics, in Copenhagen, Denmark yesterday. Androgens are hormones produced in the ovaries and adrenal glands that act on the musculoskeletal, nervous, hepatic and vascular tissues. Women actually make more androgens than estrogens daily and convert the androgens to estrogens. In adult women, androgens have long been known to play a key role in sexuality and to prevent bone loss and increase bone density. Like estrogen, androgen production drops significantly after menopause. Yet the impact of postmenopausal androgen decline has been far less studied than that of estrogen. "Androgen, for some women, is the 'missing hormone' of their postmenopausal years," said Dr. Elizabeth Barrett-Connor, who moderated the symposium and is a world-renowned expert in menopause research and professor and chief of the division of epidemiology at the University of California, San Diego, School of Medicine. These findings are exciting because they add to a growing body of research showing one-size-doesn't-fit-all in hormone replacement therapy," she added. "Hormone therapy should be tailored to each individual according to symptoms, and combination estrogen-androgen therapy can be a significantly better option for some women than estrogen alone." Loss of Libido a Common, Untreated, Symptom Many postmenopausal women experience a sharp drop in sex drive and the enjoyment and frequency of orgasm. "The decline of androgen levels after menopause is an important factor in the decline of sexual interest, yet libido remains a subject that many postmenopausal women -- and their doctors – are uncomfortable discussing," said Dr. Alex Vermeulen, MD, Ph.D., professor of medicine, University of Ghent, Belgium. "But sexuality should be just as much a part of life after menopause as before." In his presentation, Dr. Vermeulen noted that because the ovaries continue to secrete minute amounts of androgens even after menopause, women who have undergone oophorectomy (surgical removal of the uterus and ovaries) have even lower androgen levels than do women in natural menopause. Surgically menopausal women -- frequently younger and less prepared for the onset of menopausal symptoms -- may go untreated. Dr. Vermeulen cited other potential benefits of estrogen-androgen therapy, including improvements in memory abilities, increase in lean body mass and prevention of bone loss. Promising News About Osteoporosis Postmenopausal women are at increased risk for osteoporosis, a bone-thinning disease that can cause significant physical disability and shorten life expectancy. Estrogen taken after menopause has been proven to slow bone loss. But in several investigations of both postmenopausal and surgically menopausal women, estrogen plus androgen therapy was shown to not only slow bone loss, but also to stimulate bone formation. Oral estrogen-androgen therapy significantly increased bone mineral density in two, two-year studies, particularly in women who had not taken estrogen in the previous two years. Broadened Spectrum of Menopausal Symptom Relief Dr. Philip Sarrel, professor of obstetrics and gynecology and psychiatry, Yale University School of Medicine, called for a re-evaluation of the role of androgens in the treatment of postmenopausal symptoms at the time of menopause, and continuing until ten years later, when androgen levels decline even further. "The notion that menopause is a one-or two-year 'event' is an outdated way of looking at what is really a spectrum of symptoms, over as long as a decade, for many women," said Dr. Sarrel. "Androgen production, except in women undergoing surgical menopause, decreases gradually over the years leading up to menopause and for a decade later. As a result, symptoms due to androgen depletion, if any, are to be expected as the menopausal transition begins to persist into late menopause." According to Dr. Sarrel, these symptoms, observed in surgically menopausal women receiving estrogen replacement therapy, can include more severe and frequent hot flashes, more and longer-lasting symptoms due to urogenital atrophy and a greater frequency of psychologic difficulties, including mental depression and loss of libido. "Women who received estrogen plus androgen showed an improvement in sexual desire, fantasy, response and frequency and a decrease in dyspareunia compared with women who received estrogen alone," said Dr. Sarrel. Dr. Sarrel also discussed findings of a separate study of 252 women that showed 50 percent of women using estrogen-only therapy and women not taking any therapy both reported decreased libido. Also presented was a study showing improvement in symptom relief (hot flashes, insomnia and vaginal dryness) when androgens are added to estrogen regimens. "Estrogen in optimal doses provides adequate relief of hot flashes in most women, but a proportion of treated women remain dissatisfied with residual unresolved symptoms, even after taking estrogen," said Dr. Barrett-Connor. Treatment needs to be customized to each individual woman in order to obtain complete relief of persistent vasomotor symptoms. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.